Primary Analysis of Zuma-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)

This is an updated analysis of Zuma 5 – the CAR-T study of Axi-cel in follicular lymphoma (FL) and marginal zone lymphoma (MZL), initially reported in the mid-year conference season. In patients with FL, ORR rate was 94% and the CR rate was 80%. Grade 3 neurotoxicity occurred in 19% of patients with FL.